Ticker

Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings. Profitability This table compares Prime Medicine and

Brings more than 25 years of biopharma business development and corporate strategy expertise Brings more than 25 years of biopharma business development and corporate strategy expertise

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / January 13, 2026 / ATHA Energy Corp. ("ATHA" or the "Company") (TSXV:SASK)(OTCQB:SASKF)(FRA:X5U) is pleased to announce that it has entered into a binding term sheet (the "Term Sheet") with Queen's Road Capital Investment Ltd. ("QRC") for a private placement (the "Offering") of USD$20…

Hong Kong, Hong Kong--(Newsfile Corp. - January 13, 2026) - Queen's Road Capital Investment Ltd. (TSX: QRC) (the "Company" or "Queen's Road Capital") is pleased to announce that it has entered into an agreement with ATHA Energy Corp. (TSXV: SASK) ("ATHA Energy") whereby the Company will invest US$20,000,000 in ATHA Energy by way of convertible debenture.

Athira Pharma, Inc. (NASDAQ: ATHA - Get Free Report) insider Martin Javier San sold 1,644 shares of the company's stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $6.88, for a total transaction of $11,310.72. Following the completion of the transaction, the insider owned 10,189 shares